Coagulax 60 mg/0.6 ml Solution for Injection (IV/SC) Filipina - Inggeris - FDA (Food And Drug Administration)

coagulax 60 mg/0.6 ml solution for injection (iv/sc)

2 mg incorporated; distributor: 2 mg incorporated - enoxaparin sodium (drug product for emergency use) - solution for injection (iv/sc) - 60 mg/0.6 ml

Coagulax 40 mg/0.4 mL Solution for Injection (IV/SC) Filipina - Inggeris - FDA (Food And Drug Administration)

coagulax 40 mg/0.4 ml solution for injection (iv/sc)

2 mg incorporated; distributor: 2 mg incorporated - enoxaparin sodium (drug product for emergency use) - solution for injection (iv/sc) - 40 mg/0.4 ml

Enoxaparin sodium Ledraxen 10,000 IU (100 mg)/1 mL, solution for injection in pre-filled syringe Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

enoxaparin sodium ledraxen 10,000 iu (100 mg)/1 ml, solution for injection in pre-filled syringe

venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin

Enoxaparin sodium Ledraxen 2,000 IU (20 mg)/0.2 mL, solution for injection in pre-filled syringe Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

enoxaparin sodium ledraxen 2,000 iu (20 mg)/0.2 ml, solution for injection in pre-filled syringe

venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin

Enoxaparin sodium Ledraxen 4,000 IU (40 mg)/0.4 mL, solution for injection in pre-filled syringe Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

enoxaparin sodium ledraxen 4,000 iu (40 mg)/0.4 ml, solution for injection in pre-filled syringe

venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin

Enoxaparin sodium Ledraxen 6,000 IU (60 mg)/0.6 mL, solution for injection in pre-filled syringe Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

enoxaparin sodium ledraxen 6,000 iu (60 mg)/0.6 ml, solution for injection in pre-filled syringe

venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin

Enoxaparin sodium Ledraxen 8,000 IU (80 mg)/0.8 mL, solution for injection in pre-filled syringe Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

enoxaparin sodium ledraxen 8,000 iu (80 mg)/0.8 ml, solution for injection in pre-filled syringe

venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin

ENOXAPARIN SODIUM injection Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

enoxaparin sodium injection

cardinal health - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): enoxaparin sodium is indicated for: enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–q-wave myocardial infarction, when concurrently administered with aspirin. enoxaparin sodium, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute st-segment elevation myocardial infarction (stemi) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (pci). enoxaparin sodium is contraindicated in patients with: risk summary placental transfer of enoxaparin was observed in the animal studies. human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin does not increase the risk of major developmental abnormalities (see data) . based on animal data, enox

ENOXAPARIN SODIUM injection Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

enoxaparin sodium injection

cardinal health - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): enoxaparin sodium is indicated for: enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–q-wave myocardial infarction, when concurrently administered with aspirin. enoxaparin sodium, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute st-segment elevation myocardial infarction (stemi) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (pci). enoxaparin sodium is contraindicated in patients with: risk summary placental transfer of enoxaparin was observed in the animal studies. human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin does not increase the risk of major developmental abnormalities (see data) . based on animal data, enox

ENOXAPARIN SODIUM injection Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

enoxaparin sodium injection

cardinal health - enoxaparin sodium (unii: 8nz41mik1o) (enoxaparin - unii:e47c0nf7lv) - enoxaparin sodium is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe): enoxaparin sodium is indicated for: enoxaparin sodium is indicated for the prophylaxis of ischemic complications of unstable angina and non–q-wave myocardial infarction, when concurrently administered with aspirin. enoxaparin sodium, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent myocardial infarction or death in patients with acute st-segment elevation myocardial infarction (stemi) receiving thrombolysis and being managed medically or with percutaneous coronary intervention (pci). enoxaparin sodium is contraindicated in patients with: risk summary placental transfer of enoxaparin was observed in the animal studies. human data from a retrospective cohort study, which included 693 live births, suggest that enoxaparin does not increase the risk of major developmental abnormalities (see data) . based on animal data, enox